Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials

The National Institute on Aging (NIA) plans to issue a Notice of Funding Opportunity (NOFO) to support the development and implementation of multi-site clinical trials, ranging from Phase Ib to Phase III, focused on pharmacological and non-pharmacological interventions aimed at preventing, delaying, or treating symptoms associated with Alzheimer's disease and related dementias. These trials will utilize the Alzheimer's Disease Clinical Trials Consortium (ACTC) for coordination and management, fostering a collaborative partnership among applicants, NIA, and ACTC leadership, which will provide ongoing guidance. The interventions targeted will address cognitive and neuropsychiatric changes across the spectrum of disease, from pre-symptomatic stages to more advanced conditions. Although applications are not currently being accepted, the NOFO announcement serves as an advanced notification to allow potential investigators and collaborators to prepare. The funding mechanism will use the R01 activity code, inviting researchers with expertise in aging and neurodegenerative disorders to consider submitting competitive proposals once the solicitation is live. The initiative aims to facilitate innovative research and clinical trials that can contribute significantly to understanding and managing Alzheimer’s disease and related dementias. Interested parties can contact Dr. Laurie Ryan at the National Institute on Aging for further information.